The Alzheimer’s Biomarker Consortium-Down Syndrome: Rationale and methodology

Christian, PhD, B. T., and S. Hartley, PhD. The Alzheimer’s Biomarker Consortium-Down Syndrome: Rationale and Methodology.
Handen, B. L., Lott, I. T., Christian, B. T., Schupf, N., OBryant, S., Mapstone, M., Fagan, A. M., Lee, J. H., Tudorascu, D., Wang, M. C., Head, E., Klunk, W., Ances, B., Lai, F., Zaman, S., Krinsky-McHale, S., Brickman, A. M., Rosas, H. D., Cohen, A., Andrews, H., … Alzheimer’s Biomarker Consortium‐Down Syndrome (ABC‐DS) (2020). The Alzheimer’s Biomarker Consortium-Down Syndrome: Rationale and methodology. Alzheimer’s & dementia (Amsterdam, Netherlands), 12(1), e12065. https://doi.org/10.1002/dad2.12065